Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-12-21
2010-12-07
Mondesi, Robert B (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S184100, C424S234100, C424S251100, C536S023400, C536S023700, C435S069700, C530S350000
Reexamination Certificate
active
07846451
ABSTRACT:
The invention discloses theMoraxella catarrhalisouter membrane protein polypeptide and polypeptides derived therefrom (collectively “OMP21”), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also disclosed are pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions including vaccines, comprising OMP21, antibodies thereto or nucleotides encoding same. The invention additionally discloses methods of inducing an immune response toM. catarrhalisand OMP21 in an animal, preferably a human, methods of treating and methods of diagnosingMoraxellainfections in an animal, preferably a human, and kits therefor.
REFERENCES:
patent: 5604131 (1997-02-01), Wadsworth et al.
patent: 5607846 (1997-03-01), Murphy et al.
patent: 5808024 (1998-09-01), Sasaki et al.
patent: 6090576 (2000-07-01), Myers et al.
patent: 6214981 (2001-04-01), Tucker et al.
patent: 7311917 (2007-12-01), Tucker et al.
patent: 0 614 989 (1994-09-01), None
patent: 614989 (1994-09-01), None
patent: WO-93/25708 (1993-12-01), None
patent: WO-95/21922 (1995-08-01), None
patent: WO-96/12733 (1996-05-01), None
patent: WO-96/34960 (1996-11-01), None
patent: WO-97/41731 (1997-11-01), None
patent: WO-99/58563 (1999-11-01), None
Houghten et al. (Vaccines, 1986, Edited by Fred Brown: Cold Spring Harbor Laboratory).
Holmes, Exp. Opin.lnvest. Drugs, 2001, 10(3):511-519.
Greenspan et al (Nature Biotechnology, 1999, 7:936-937).
Ahmed et al., Microbiol. Immunol., 36(6):563-573 (1992).
Ahmed, et al., Microbiol. Immunol. 36(10):1009-1017 (1992).
Ausubel, et al., Eds. 1994, Current Protocols in Molecular Biology, 3: 16.5.1-16.11.10.
Bartos, et al., J. Infect. Dis. 158(4):761-765 (1988).
Bogosian, et al.,“Genome Rearrangements by Residual IS10 Elements in Strains ofEscherichia coliK-12 Which Had Undergone Tn10 Mutagenesis and Fusaric Acid Selection,” Gene. 133(1):17-22.
Burgess, et al., Journal of Cell Biology, 111:2129-2138, 1990.
Catlin, et al., 1990, “Branhamella catarrhalis: An Organism Gaining Respect as a Pathogen,” Clin Microbil Rev. 3:293-320.
Christensen,et al., Clin Diagn Lab Immunol., Nov. 1996, 3(6): 717-21.
Cohen, 1993, “Naked DNA Points Way to Vaccines,” Science, 295(5102): 1691-1692.
Current Protocols in Immunology, 1997, Unit 9.7.5.
Helminen, et al., 1992, “A Major Outer Membrane Protein ofMoraxella catarrhalisis a Target for Antibodies that Enhance Pulminary Clearance of the Pathogen in an Animal Model,” Infect. Immun., 61:2003-2010.
Helminen, et al., 1994, “A Large, Antigenically Conserved Protein on the Surface ofMoraxella catarrhallisis a Target for Protective Anitbodies,” J. Infect. Dis., 170: 867-872.
Inder M. Verma et al., 1CGene Therapy 14promises, problems and prospects 1D, Nature, vol. 389, Sep. 18, 1997, pp. 239 14242.
Jobling, et al., Mol. Microbiol., 1991, 5(7): 1755-67.
Kellens, et al., 1995, “Evidence for Lectin-Mediated Adherence ofMoraxella catarrhalis,” Infection 223:37-41.
Kellens, et al., Infection, 23(1):37/41-41-45 (1995).
Klingman, et al., 1994, “Purification and Characterization of a High Molecular Weight Outer Membrane Protein ofMoraxella(Branhamella)catarrhalis,” Infect Immun 62:1150-1155.
Lazar, et al., Molecular and Cellular Biology, 8(3): 1247-1252, 1988.
Mbaki, et al., 1987, Correlation BetweenBranhamella catarrhalisAdherence to Oropharyngeal Cells and Seasonal Incidence of Lower Respirator Tract Infections, Tohuku J. Exp. Med., 13: 111-121.
McMichael, 2000, Microbes and Infection, 2: 561-568.
Murphy, et al., Infec. Immun. 57(10):293802941 (1989).
Murphy, et al., Microbial Pathogenesis, 6:159-174 (1989).
Murphy, Pediatr. Infect. Dis, 8:S750-S77 (1989).
Murphy,et al., 1993, “The Major Heat-Modifiable Outer Membrane Protein CD is Highly Conserved Among Strains ofBranhamella catarrhalis,” Molec. Microbiol. 10:87-97.
Reece, et al., J. Immunol. 1994, vol. 172, p. 241.
Rikitomi, et al., J. Infect. Dis. 23:559-567 (1991).
Rodinger, et al., “Peptide Hormones,” edited by Parsons, J.A., University Park Press, Jun. 1976, 1-5.
Sakuma, et al., NCBI Genbank Accession No. D83266, 1996.
Sarwar, et al., 1992, “Characterization of an Antigenically Conserved Heat-Modifiable Major OUter Membrane Protein ofBranhamella catarrhalis,” Infect Immun, 60:804-809.
Sedegah, et al., 1994, “Protection Against Malaria by Immunication with Plasmid DNA Encoding Circumsporozoite Protein,” Proc. Natl. Acad. Sci. USA, 91(21): 9866-9870.
Sedegah, et al., 1998, “Boosting with Recombinant Vaccinia Increases Immunogenicity and Protective Efficacy of Malaria DNA Vaccine,” Proc. Natl. Acad. Sci, USA, 95: 7648-7653.
Soto Hernandez,et al., 1989, “Phenotypic Characteristics ofBranhamella catarrhalisStrains,” J. Clin. Microbiol. 27:903-908.
Tucker, et al., 1989, Annual Meeting of Amer. Soc. Microbiol. Abstract. K124.
Ulmer, et al., 1993, “Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Proten,” Science, 259: 1745-1749.
Unhanand, et al., 1992, “Pulmonary Clearance ofMoraxella catarrhalisin an Animal Model,” J. Infect Dis. 165:644-650.
Wang, et al., 1998, “Induction of Antigen-Specific Cytotoxic T Lymphocytes in Humans by a Malaria DNA Vaccine,” Science, 282(5388): 476-480.
Japanese Office Action with English translation corresponding to JP Application No. 2000-572357, dated Sep. 1, 2009, 13 pages.
Tillman Ulrich F.
Tucker Kenneth
Baskar Padma V
Emergent Product Development Gaithersburg Inc.
K&L Gates LLP
Mondesi Robert B
LandOfFree
Moraxella catarrhalis protein, nucleic acid sequence and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Moraxella catarrhalis protein, nucleic acid sequence and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Moraxella catarrhalis protein, nucleic acid sequence and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4189165